Haleon (HLN) Receivables - Net (2021 - 2026)

Haleon's (HLN) quarterly Receivables - Net came in at $3.1 billion in Q2 2026, up 11.38% on a QoQ basis from $2.8 billion in Q4 2025.

Haleon (HLN) Receivables - Net (2021 - 2026) Analysis & Trends

Haleon (HLN) has 6 years of Receivables - Net data on file, last reported at $3.1 billion in Q2 2026.

Quarterly Receivables - Net changed N/A year-over-year to $3.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.1 billion (changed N/A YoY) and the FY2025 annual result came in at $2.8 billion, up 2.54% from the prior year.
Receivables - Net advanced to $3.1 billion in Q2 2026, from $2.8 billion in the prior quarter.
In the past five years, Receivables - Net ranged from a high of $3.1 billion in Q2 2026 to a low of $2.4 billion in Q4 2022.
A 5-year average of $2.7 billion and a median of $2.7 billion in 2024 frame the typical range for Receivables - Net.
Annual changes were most pronounced in 2022 — Receivables - Net declined 20.64% — and 2024, when it climbed 7.87%.
Tracing HLN's Receivables - Net over 5 years: stood at $2.4 billion in 2022, then grew by 3.56% to $2.4 billion in 2023, then gained by 7.87% to $2.6 billion in 2024, then grew by 4.54% to $2.8 billion in 2025, then gained by 11.38% to $3.1 billion in 2026.
The last three Receivables - Net figures came in at $3.1 billion (Q2 2026), $2.8 billion (Q4 2025), and $2.6 billion (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-
2	Teva Pharmaceutical Industries	43.42 Bn	39.76 Bn	2.15 Bn
3	Zoetis	31.86 Bn	30.18 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.77 Bn	22.98 Bn	5.10 Bn
5	United Therapeutics	22.29 Bn	19.63 Bn	683.80 Mn
6	Viatris	18.78 Bn	17.89 Bn	1.46 Bn
7	Neurocrine Biosciences	15.66 Bn	15.27 Bn	935.80 Mn
8	Elanco Animal Health	11.91 Bn	11.38 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-
10	Alkermes	8.20 Bn	7.55 Bn	397.90 Mn

Download Data